Drug Profile
Research programme: riminophenazine tuberculosis therapies - Materia Medica/TB Alliance
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Institute of Materia Medica
- Developer Global Alliance for TB Drug Development; Institute of Materia Medica
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Tuberculosis in China
- 02 Feb 2007 Preclinical trials in Tuberculosis in China (unspecified route)